Journal of Clinical Oncology
Articles in this Issue
PORTOS gene signature as a predictor of risk of adverse events after dose-escalated vs. lower-dose prostate radiation therapy in NRG/RTOG 0126.
375 Background: Dose-escalated radiation therapy is standard treatment for patients with prostate cancer. Dose-escalation improves cancer control but also...
Impact of adherence to a remote exercise program on health-related quality of life in prostate cancer patients undergoing treatment: A prospective study in Brazil.
130 Background: Patients with metastatic prostate cancer (mPCa) undergoing treatment often experience declines in health-related quality of life (HRQoL) a...
Platelet-to-lymphocyte ratio as a useful biomarker of recurrence and mortality risks in patients with muscle-invasive bladder cancer who achieved ypT0 to neoadjuvant chemotherapy: A multicenter retrospective study.
873 Background: Platelet-to-lymphocyte ratio (PLR), a novel inflammatory marker, has been suggested to predict recurrence and mortality in several maligna...
Molecular subtypes, <i>NECTIN4/HER2</i> expression, and clinical outcomes in patients (pts) with advanced urothelial carcinoma (aUC) or muscle invasive bladder cancer (MIBC): Exploratory analyses from JAVELIN Bladder 100 and the Tempus database.
828 Background: Consensus molecular subtypes of UC/BC include basal/squamous (Ba/Sq), stroma-rich (SR), luminal unstable (lumU), luminal papillary (lumP),...
Radical prostatectomy (RP) versus radiotherapy (RT) in high-risk prostate cancer (HR-PCa): Emulated randomized comparison with individual patient data (IPD) from two phase III randomized trials (RCTs).
309 Background: Standard of care (SOC) treatment options for HR-PCa include RT with long-term androgen deprivation (LT-ADT) or RP with selective use of po...
Protein analysis of urachal carcinoma tissue based on different antibody-drug conjugate therapeutic targets.
852 Background: Urachal carcinoma (UrC) is an extremely rare cancer, and there is still a lack of standard drug treatment models for advanced UrC. Antibod...
Immune checkpoint inhibitors in patients with testicular cancer: A systematic review.
638 Background: Germ cell tumors (GCT) are chemosensitive neoplasms with high cure rates, even in the metastatic setting. However, a small group of these...
Neuropathy, skin rash, and hyperglycemia as predictors of response to enfortumab vedotin in locally advanced and metastatic bladder and upper tract urothelial carcinoma.
771 Background: Enfortumab vedotin (EV) in combination with pembrolizumab is FDA approved for treatment of locally advanced and metastatic urothelial canc...
Phase 2 study of perioperative lenvatinib (L) with pembrolizumab (P) in patients with locally advanced nonmetastatic clear cell renal cell carcinoma.
555 Background: L is an oral multi-kinase inhibitor targeting vascular endothelial growth factor receptors 1-3, fibroblast growth factor receptors 1-4, pl...
Study of JAK inhibition in stem-like prostate cancer (JASPER): A phase 1/2 multicenter study of ruxolitinib and enzalutamide in castration resistant prostate cancer undergoing lineage plasticity.
TPS297 Background: Lineage plasticity (LP) is an increasingly recognized route of resistance in advanced metastatic prostate cancer, and present in approx...
Efficacy and safety of fruquintinib combined with serplulimab as 1 <sup>st</sup> line treatment in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated results from a single-arm, multicentre clinical trial.
542 Background: For advanced non-clear cell renal cell carcinoma (nccRCC), systemic therapy is the main option but the treatment standard remains unclear....
Dose finding study of CBM588 in combination with nivolumab and ipilimumab in patients with metastatic renal cell carcinoma: A phase I study.
TPS611 Background: The combination of nivolumab and ipilimumab is currently one of the standard-of-care treatments for patients with metastatic renal cell...
Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
663 Background: Dato-DXd is a TROP2-directed antibody-drug conjugate under investigation in various solid tumor types. We report updated results in patien...
Evaluating neoadjuvant intravesical mitomycin C in NMIBC: A phase III randomized clinical trial.
803 Background: The primary treatment for non-muscle invasive bladder cancer (NMIBC) is transurethral resection (TUR), often followed by adjuvant intraves...
Darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer (mHSPC) by disease volume: Subgroup analysis of the phase 3 ARANOTE trial.
151 Background: Darolutamide (DARO) plus ADT significantly reduced the risk of radiological progression or death by 46% (HR 0.54; 95% CI: 0.41–0.71;...
Clinicopathological characteristics and prognosis of metastatic non-clear cell renal cell carcinoma.
504 Background: Non-clear cell renal cell carcinoma (nccRCC) is a clinicopathological heterogeneous disease that comprises a complex mixture of different...
The feasibility of tumor-infiltrating lymphocyte expansion in non-clear cell renal cell carcinoma.
580 Background: The treatment landscape for non-clear cell renal cell carcinoma (nccRCC) lacks personalized therapeutic options. Although adoptive cell th...
Real-world treatment patterns and outcomes in advanced prostate cancer: A cohort study using the prostate cancer disease observation (PRECISION) data platform.
59 Background: There are several real-world data sources for prostate cancer (PC), each with its own limitations; the most notable limitation is an incomp...
Treatment patterns and survival outcomes in metastatic castration-resistant prostate cancer in the Brazilian population: LACOG 1818.
27 Background: Prostate cancer is the second leading cause of cancer death in men worldwide. In Brazil, 75% of patients (pts) rely on the public healthcar...
A prognostic biomarker panel for chromophobe renal cell carcinoma using immunohistochemistry.
596 Background: The American Cancer Society estimates 14,390 deaths from kidney cancer in 2024 Chromophobe renal cell carcinoma (chRCC) is the third most...
Circulating tumor cell (CTC) expression patterns of cell surface targets in metastatic prostate cancer.
232 Background: Resistance to first-line Androgen Receptor Pathway Inhibitors (ARPI) in metastatic prostate cancer (mPC) is universal and can be driven by...
Extracellular DNA in patients with urothelial carcinoma of the bladder.
834 Background: Higher concentration of extracellular DNA (ecDNA) in plasma of subjects with various cancers is associated with worse prognosis. The assoc...
Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial.
246 Background: Serum androgen levels are prognostic in mCRPC and genetic variation in androgen metabolism may drive these effects. OATPs, encoded by gene...
Cabozantinib (C) ± atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Expansion cohorts from the open-label phase 1b COSMIC-021 study.
145 Background: The phase 3 CONTACT-02 study significantly improved PFS and showed a trend in OS benefit with C+A vs a second novel hormone therapy (NHT)...
Real world comparison of time-to-next-treatment (TTNT), time-to-castration-resistance (TTCR), and overall survival (OS) among patients with <i>BRCA1/2</i> positive and homologous recombination repair (HRR) negative metastatic castration-sensitive prostate cancer (mCSPC).
77 Background: Patients with mCSPC harboring genetic alterations in HRR genes, particularly BRCA1/2 , may experience aggressive di...